Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 18

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 18
---
 Association, the Biotech Institute and the Emerging Companies Section of the Biotechnology Innovation Organization. He holds a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive). Our Board and Nominating Committee believes that Mr. Morrison’s 40 years of experience serving life sciences companies and in public accounting as well as many years of governance experience qualifies him to serve on our Board. Christy Oliger, 55, has served as a member of our Board since June 2024. Ms. Oliger currently serves on multiple public company boards, including Karyopharm Therapeutics (Nasdaq: KPTI), a biopharmaceutical company, since August 2020, Replimune Group (Nasdaq: REPL), a biotechnology company, since December 2021 and LAVA Therapeutics (Nasdaq: LVTX), a biopharmaceutical company, since March 2023. She previously served on the boards of Sierra Oncology from June 2021 until its acquisition by GSK in July 2022, Reata Pharmaceuticals from April 2021 until its acquisition by Biogen in June 2023, and RayzeBio from August 2023 until its acquisition by Bristol Myers Squibb in February 2024. In her most recent operational role, Ms. Oliger served as Genentech’s Senior Vice President, Oncology Business Unit Head from 2017 to 2020. During her 20-year tenure at Genentech, she held senior commercial leadership roles across a variety of therapeutic areas, including oncology, neurology, rare disease, respiratory, dermatology, and immunology. In addition, while at Genentech Ms. Oliger held senior R&D roles, including leading the Roche global portfolio management function. Ms. Oliger holds a Bachelor of Arts in Economics from the University of California at Santa Barbara. Our Board and Nominating Committee believes that Ms. Oliger’s experience serving life sciences companies as an execute and as a director qualifies her to serve on our Board. 10 TABLE OF CONTENTS INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE Independence of the Board of Directors As required under the Nasdaq Stock Market (“Nasdaq”) listing rules, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. The Board consults with the Company’s counsel to ensure that